Literature DB >> 14550847

Genetic and pharmacological aspects of histamine H3 receptor heterogeneity.

Arthur A Hancock1, Timothy A Esbenshade, Kathleen M Krueger, Betty Bei Yao.   

Abstract

Histaminergic H3 receptors modulate the release of neurotransmitters within the CNS and periphery. Ligands for these receptors have potential clinical utility in a variety of disease states. However, the pharmacological characteristics of these receptors have been enigmatic for more than a decade because of the diversity of pharmacological effects observed with the limited number of heretofore-available compounds. Recent cloning of the H3 receptor has revealed interspecies differences in the protein sequences in key regions, the existence of splice variants that differ in composition between species, and potential differences in signal transduction processes between either different tissues and/or species. This review attempts to summarize these findings within the context of the molecular biological and pharmacological data accumulated to date. Also, we suggest a nomenclature strategy to reduce potential confusion that has arisen from different naming systems used by various investigators. While some facets of this genetic and pharmacological diversity help to rationalize various aspects of H3 receptor heterogeneity, there remains an insufficient repertoire of selective ligands, assays, or other measures to completely resolve all components of this diversity. The promise of newly available tools to further explore H3 receptor function may provide the insight to bring the promised clinical potential of H3 receptor ligands to realization.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14550847     DOI: 10.1016/j.lfs.2003.06.003

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  12 in total

Review 1.  Central nervous system biogenic amine targets for control of appetite and energy expenditure.

Authors:  David L Nelson; Donald R Gehlert
Journal:  Endocrine       Date:  2006-02       Impact factor: 3.633

Review 2.  The histamine H3 receptor: an attractive target for the treatment of cognitive disorders.

Authors:  T A Esbenshade; K E Browman; R S Bitner; M Strakhova; M D Cowart; J D Brioni
Journal:  Br J Pharmacol       Date:  2008-05-12       Impact factor: 8.739

Review 3.  International Union of Basic and Clinical Pharmacology. XCVIII. Histamine Receptors.

Authors:  Pertti Panula; Paul L Chazot; Marlon Cowart; Ralf Gutzmer; Rob Leurs; Wai L S Liu; Holger Stark; Robin L Thurmond; Helmut L Haas
Journal:  Pharmacol Rev       Date:  2015-07       Impact factor: 25.468

Review 4.  Histamine H3 receptor antagonists in relation to epilepsy and neurodegeneration: a systemic consideration of recent progress and perspectives.

Authors:  M Bhowmik; R Khanam; D Vohora
Journal:  Br J Pharmacol       Date:  2012-12       Impact factor: 8.739

5.  The histamine autoreceptor is a short isoform of the H₃ receptor.

Authors:  F Gbahou; A Rouleau; J-M Arrang
Journal:  Br J Pharmacol       Date:  2012-07       Impact factor: 8.739

Review 6.  Mouse behavioural analysis in systems biology.

Authors:  Peter Van Meer; Jacob Raber
Journal:  Biochem J       Date:  2005-08-01       Impact factor: 3.857

7.  Generation of a homology model of the human histamine H(3) receptor for ligand docking and pharmacophore-based screening.

Authors:  Birgit Schlegel; Christian Laggner; Rene Meier; Thierry Langer; David Schnell; Roland Seifert; Holger Stark; Hans-Dieter Höltje; Wolfgang Sippl
Journal:  J Comput Aided Mol Des       Date:  2007-08-01       Impact factor: 3.686

8.  Histamine excites neurones in the human submucous plexus through activation of H1, H2, H3 and H4 receptors.

Authors:  Eva Breunig; Klaus Michel; Florian Zeller; Stefan Seidl; Claus Werner Hann v Weyhern; Michael Schemann
Journal:  J Physiol       Date:  2007-07-12       Impact factor: 5.182

9.  Differential effects of acute and repeat dosing with the H3 antagonist GSK189254 on the sleep-wake cycle and narcoleptic episodes in Ox-/- mice.

Authors:  R X Guo; C Anaclet; J C Roberts; R Parmentier; M Zhang; G Guidon; C Buda; J P Sastre; J Q Feng; P Franco; S H Brown; N Upton; A D Medhurst; J S Lin
Journal:  Br J Pharmacol       Date:  2009-05       Impact factor: 8.739

10.  H3 histamine receptor antagonist pitolisant reverses some subchronic disturbances induced by olanzapine in mice.

Authors:  Magdalena Dudek; Kamil Kuder; Marcin Kołaczkowski; Adrian Olczyk; Elżbieta Żmudzka; Aleksandra Rak; Marek Bednarski; Karolina Pytka; Jacek Sapa; Katarzyna Kieć-Kononowicz
Journal:  Metab Brain Dis       Date:  2016-05-24       Impact factor: 3.584

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.